Cover Image
Market Research Report

Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Majority of the Manufacturing Activity

Published by GBI Research Product code 246716
Published Content info 105 Pages
Immediate Delivery Available
Price
Back to Top
Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Majority of the Manufacturing Activity
Published: July 10, 2012 Content info: 105 Pages
Description

Summary

GBI Research's report, "Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Majority of the Manufacturing Activity" provides detailed insight into the Europe API market. The research presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region. The report contains market forecasts, product type analysis, drivers and restraints. In addition, it includes market forecasts, product type analysis, therapeutic categories analysis and CMO growth in the region and its influence on API manufacturing activity towards 2017. Overall, the report presents a comprehensive analysis of the Europe API market, covering all the major parameters.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Europe is the third largest regional market for APIs by revenue in the world. European active pharmaceutical ingredients (API) market revenue held a share of around 24.2% of global API market revenue of 108.6 $ billion in 2011. Total revenue generated by the European API market was $26,288.96 million in 2011 and is expected to grow at a CAGR of 6.5% to reach $38,255.67 million by 2017.This will be supported by healthy demand from generic and biotech API sectors.

Scope

  • Market revenue data for APIs from 2005 to 2011 and forecast for six years to 2017.
  • API markets in key countries in the region: Germany, France, Italy, the Uk, Spain
  • API industry structure and market trends such as a shift in manufacturing and growth in biotechnology for the Europe region.
  • Drivers of the API market, such as the growth of generic drugs, and restraints, such as patent expiries and government initiatives like price reimbursement cut.
  • Detailed historical, forecast trend and share analysis of API revenue based on product types (Synthetic and Biotech APIs) in the Europe market and in key countries of the region.
  • Detailed historical, forecast trend and share analysis of API revenue based on customer base (Generic and Innovative for Synthetic APIs) (Biosimilars and biologics for Biotech Apis) in the Europe market and in key countries of the region.
  • Analysis of API revenue based on therapeutic categories in the Europe and key countries.

Reasons to buy

  • Develop business strategies with the help of specific insights on the Europe API market.
  • Identify opportunities and challenges in the Europe API market.
  • Invest in the growing segments of the API market.
  • Increase future revenue and profitability with the help of insights on the future opportunities and critical success factors in the Europe API market.
  • Benchmark your operations and strategies against the major players in the global API market.
  • Keywords
  • API,Generic API, Branded API,Biotech, generic, innovator drug, therapeutic, Biologics, Biosimilars

Executive Summary

Austerity Pricing Tactics Support Generic Drug Growth in Europe.

Government initiatives to cut health expenditure are likely to encourage sales of generic medications in Europe, according to a new report by healthcare experts GBI Research.

The new report* predicts an increase in revenue made by generics in the region during the next five years, as cost-containment policies strongly support the consumption of generic drugs over innovative drug use.

Biosimilars are a category of generics, also referred to as generic biotech Active Pharmaceutical Ingredients (API), or follow-on biologics (FOB). API derived from biotechnology provide high-growth market potential, but are expensive to develop and manufacture compared to the production of regular small molecule generic API.

France, Germany and the UK have all tightened their healthcare budgets to tackle the economic crisis, resulting in pressure to reduce pharmaceutical prices. This is bringing about changes in healthcare pricing and reimbursement across the continent. Reimbursement restrictions are applied to drugs that are priced higher than the reference price, and will restrict the growth of the innovative and biologic API markets during the next few years.

However, while reimbursement cuts are expected to decrease the use of innovative, drugs and hinder API revenue, luckily API generics look set to remain popular.

The expiry of patents for major blockbuster drugs and the entry of low-priced generic versions are expected to increase the consumption of generic drugs, with the weak pipelines of major pharmaceutical companies amplifying this trend. With many patent expiries occurring during 2010-2012, generic consumption is expected to peak, and in turn increase the competition between pharmaceutical producers.

The European API market accounted for around 24.2% of the global API market revenue of $108.6 billion in 2011. Germany and France were the market leaders, with Italy and the UK trailing in third and fourth.

The remaining shares of the market depict the emergence of contract manufacturing organization (CMO) activity and improvement in GDP in Central and Eastern European economies, which have driven up the health care market during recent years. Most Eastern European countries possess good business infrastructure and offer excellent business opportunities for API manufacturing, which is expected to drive the API CMO market in the region during the forecast period. According to GBI Research estimates, the overall CMO market in Eastern and Central Europe countries is expected to witness a healthy CAGR of 14.1% to 2017. This increase in CMO activity is expected to capture most of the API manufacturing activity towards 2017.

The API market in Europe accounted for revenue of $19,868.39m in 2005, which grew at a CAGR of 4.8% to $26 billion in 2011. The market is expected to grow further at a CAGR of 6.5% to reach $38 billion by 2017. This will be supported by healthy demand from the generic and biotech API sectors.

Active Pharmaceutical Ingredients (API) Market in Europe to 2017 - Pricing and Reimbursement Initiatives Supporting Generic Drug Growth, with CMOs Expected to Account for Majority of the Manufacturing Activity

This report provides detailed insight into the Europe API market, and presents detailed analysis and forecasts of the major economic and market trends affecting the API markets in this region. The report contains market forecasts, product type analysis, drivers and restraints. In addition, it includes market forecasts, product type analysis, therapeutic categories analysis and CMO growth in the region and its influence on API manufacturing activity towards 2017. Overall, the report presents a comprehensive analysis of the Europe API market, covering all the major parameters.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Contract Manufacturing Organizations (CMO) an Upcoming Trend in Europe API Manufacturing

  • 3.1. Introduction
    • 3.1.1. How Does Outsourcing to CMOs Take Place?
  • 3.2. Europe CMO Market Drivers
    • 3.2.1. Availability of Low-Cost Skilled Manpower
    • 3.2.2. Key Benefits of API Manufacturing Outsourcing in Europe
  • 3.3. The Eastern European CMO Market

4. Europe Active Pharmaceutical Ingredients Market

  • 4.1. Market Overview
  • 4.2. API Classification
    • 4.2.1. API Classification Based on Synthesis Routes
    • 4.2.2. Types based on Customer Base
  • 4.3. Industry Structure
  • 4.4. Europe API Market Drivers
    • 4.4.1. Increased CMO Opportunities is Expected to Improve the Production of Generics and Fuel the Revenues of API in the Region
    • 4.4.2. Overall Growth in the Pharmaceutical Industry and Increasing Elderly Population are Driving the Growth of the European API Market
    • 4.4.3. Attractiveness towards Biopharmaceutical Therapies Supports the Growth of the API Market in Europe
    • 4.4.4. European Regulatory Framework Facilitating Development of Biosimilars
    • 4.4.5. Differences in VAT rates on Pharma Products is Expected to Increase Parallel Trade in Europe
  • 4.5. Europe API Market Restraints
    • 4.5.1. Increased Consumption of Generics
    • 4.5.2. Increasing Patent Expiries Hamper the Growth of the European API Market
    • 4.5.3. Price Cuts Restrict the Revenue Growth of the European API Market
  • 4.6. Europe API Total Revenue Analysis
  • 4.7. Europe Revenue Share by Product Types
  • 4.8. Europe Synthetic API Market Analysis
    • 4.8.1. Europe Synthetic API Market Drivers
    • 4.8.2. Europe Synthetic API Market Restraints
    • 4.8.3. Europe Synthetic API Total Synthetic Revenue Analysis 2005-2017
    • 4.8.4. European Synthetic API Market Revenue Share Analysis Based on Customer Base in 2011
    • 4.8.5. Europe Synthetic API Revenue Trend Analysis 2005-2017
  • 4.9. Europe Biotech API Market Analysis
    • 4.9.1. Europe Biotech API Market Drivers
    • 4.9.2. Europe Biotech API Market Restraints
    • 4.9.3. Europe Biotech API Revenue Analysis 2005-2017
  • 4.10. Europe Biotech API Market Revenue Analysis by Customer Base
    • 4.10.1. Europe Biotech API Market Revenue Share Analysis by Customer Base
  • 4.11. Europe Patent Expiry of Leading Biologics
  • 4.12. Europe API Revenue Split Up by Therapeutic Applications

5. Germany Active Pharmaceutical Ingredients Market

  • 5.1. Germany API Market Overview
  • 5.2. Germany Total API Revenue Analysis based on the synthesis routes 2005-2017
  • 5.3. Germany API Revenue Share Analysis by Product Types 2005-2017
  • 5.4. Germany API Revenue Analysis based on Customer Base
    • 5.4.1. Germany Synthetic API Revenue Analysis by Customer Base, 2005-2017
    • 5.4.2. Germany Synthetic API Market Revenue Share Analysis by Customer Base, 2005-2017
    • 5.4.3. Germany Biotech API Revenue Analysis by Customer Base, 2005-2017
    • 5.4.4. Germany Biotech API Revenue Share Analysis by Customer Base, 2005-2017
  • 5.5. Germany API Revenue share Analysis by Therapeutic Applications

6. France Active Pharmaceutical Ingredients Market

  • 6.1. France API Market Overview
  • 6.2. France Total API Revenue Analysis Based on Synthesis Routes 2005-2017
  • 6.3. France API Revenue Share Analysis by Product Types 2005-2017
  • 6.4. France API Revenue Analysis based on Customer Base
    • 6.4.1. France Synthetic API Revenue Analysis by Customer Base, 2005-2017
    • 6.4.2. France Synthetic API Market Revenue Share Analysis by Customer Base, 2005-2017
    • 6.4.3. France Biotech API Revenue Analysis by Customer Base, 2005-2017
    • 6.4.4. France Biotech API Revenue Share Analysis by Customer Base, 2005-2017
  • 6.5. France API Revenue share Analysis by Therapeutic Applications

7. Italy Active Pharmaceutical Ingredients Market

  • 7.1. Italy API Market Overview
  • 7.2. Italy Total API Revenue Analysis based on Synthesis Routes 2005-2017
  • 7.3. Italy API Revenue Share Analysis by Product Types 2005-2017
  • 7.4. Italy API Revenue Analysis based on Customer Base
    • 7.4.1. Italy Synthetic API Revenue Analysis by Customer Base, 2005-2017
    • 7.4.2. Italy Synthetic API Market Revenue Share Analysis by Customer Base, 2005-2017
    • 7.4.3. Italy Biotech API Revenue Analysis by Customer Base, 2005-2017
    • 7.4.4. Italy Biotech API Revenue Share Analysis by Customer Base, 2005-2017
  • 7.5. Italy API Revenue share Analysis by Therapeutic Applications

8. The UK Active Pharmaceutical Ingredients Market

  • 8.1. The UK API Market Overview
  • 8.2. The UK Total API Revenue Analysis based on Synthesis Routes 2005-2017
  • 8.3. The UK API Revenue Share Analysis by Product Types 2005-2017
  • 8.4. The UK API Revenue Analysis based on Customer Base
    • 8.4.1. The UK Synthetic API Revenue Analysis by Customer Base, 2005-2017
    • 8.4.2. The UK Synthetic API Market Revenue Share Analysis by Customer Base, 2005-2017
    • 8.4.3. The UK Biotech API Revenue Analysis by Customer Base, 2005-2017
    • 8.4.4. The UK Biotech API Revenue Share Analysis by Customer Base, 2005-2017
  • 8.5. The UK API Revenue share Analysis by Therapeutic Applications

9. Spain Active Pharmaceutical Ingredients Market

  • 9.1. Spain API Market Overview
  • 9.2. Spain Total API Revenue Analysis based on Synthesis Routes 2005-2017
  • 9.3. Spain API Revenue Share Analysis by Product Types 2005-2017
  • 9.4. Spain API Revenue Analysis based on Customer Base
    • 9.4.1. Spain Synthetic API Revenue Analysis by Customer Base, 2005-2017
    • 9.4.2. Spain Synthetic API Market Revenue Share Analysis by Customer Base, 2005-2017
    • 9.4.3. Spain Biotech API Revenue Analysis by Customer Base, 2005-2017
    • 9.4.4. Spain Biotech API Revenue Share Analysis by Customer Base, 2005-2017
  • 9.5. Spain API Revenue share Analysis by Therapeutic Applications

10. Appendix

  • 10.1. Abbreviations
  • 10.2. Market Definitions
  • 10.3. References
  • 10.4. Methodology
    • 10.4.1. Coverage
    • 10.4.2. Secondary Research
    • 10.4.3. Primary Research
    • 10.4.4. Expert Panel Validation
  • 10.5. Contact Us
  • 10.6. Disclaimer

List of Tables

  • Table 1: CMO Market, Europe, All Employees:Index of Hourly Compensation Costs (United States = 100),
  • Table 2: CMO Market, The Central and Eastern Europe, Revenue Analysis ($bn), 2005-2017
  • Table 3: Pricing and Reimbursement Mechanism in the Top Five Countries of Europe
  • Table 4: API, Europe , Total Revenue Analysis, $m, 2005-2017
  • Table 5: API, Europe, Revenue Share by Product Types, (%) 2011
  • Table 6: Synthetic API, Europe , Revenue Analysis, $m, 2005-2017
  • Table 7: Synthetic API, Europe, Revenue Share Analysis by Countries, (%) 2011
  • Table 8: Synthetic API, Europe, Revenue Share Trend, %, 2005-2017
  • Table 9: Synthetic API, Europe, Revenue Share by Customer Base, (%), 2011
  • Table 10: Synthetic API, Europe, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 11: Biotech API, Europe, Revenue Analysis, ($m), 2005-2017
  • Table 12: Biotech API, Europe, Revenue Share by Countries, %, 2011
  • Table 13: Biotech API, Europe, Revenue Share Trend, %, 2005-2017
  • Table 14: Europe Biotech API Market, Revenue Share Analysis by Sectors Based on Customer Base, 2011
  • Table 15: Biotech API, Europe, Key Patent Expiry of Leading Biologics , 2005 To 2017
  • Table 16: Biotech API, Europe, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 17: API, Europe, Revenue Split by Therapeutic Applications, %, 2011-2017
  • Table 18: API, Germany, Revenue Analysis by Product Types, $m, 2005-2017
  • Table 19: API, Germany, Revenue Share by Product Type, %, 2005-2017
  • Table 20: Synthetic API, Germany, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 21: Synthetic API, Germany, Revenue Share by Customer Base, %, 2005-2017
  • Table 22: Biotech API, Germany, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 23: Biotech API, Germany, Revenue Share by Customer Base, %, 2005-2017
  • Table 24: API, Germany, Revenue Split by Therapeutic Applications, %, 2011-2017
  • Table 25: API, France, Revenue Analysis by Product Types, $m, 2005-2017
  • Table 26: API, France, Revenue Share by Product Type, %, 2005-2017
  • Table 27: Synthetic API, France, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 28: Synthetic API, France, Revenue Share by Customer Base, %, 2005-2017
  • Table 29: Biotech API, France, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 30: Biotech API, France, Revenue Share by Customer Base, %, 2005-2017
  • Table 31: API, France, Revenue Split by Therapeutic Applications, %, 2011-2017
  • Table 32: API, Italy, Revenue Analysis by Product Types, $m, 2005-2017
  • Table 33: API, Italy, Revenue Share by Product Type, %, 2005-2017
  • Table 34: Synthetic API, Italy, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 35: Synthetic API, Italy, Revenue Share by Customer Base, %, 2005-2017
  • Table 36: Biotech API, Italy, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 37: Biotech API, Italy, Revenue Share by Customer Base, %, 2005-2017
  • Table 38: API, Italy, Revenue Split by Therapeutic Applications, %, 2011-2017
  • Table 39: API, The UK, Revenue Analysis by Product Types, $m, 2005-2017
  • Table 40: API, The UK, Revenue Share by Product Type, %, 2005-2017
  • Table 41: Synthetic API, The UK, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 42: Synthetic API, The UK, Revenue Share by Customer Base, %, 2005-2017
  • Table 43: Biotech API, The UK, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 44: Biotech API, The UK, Revenue Share by Customer Base, %, 2005-2017
  • Table 45: API, The UK, Revenue Split by Therapeutic Applications, %, 2011-2017
  • Table 46: API, Spain, Revenue Analysis by Product Types, $m, 2005-2017
  • Table 47: API, Spain, Revenue Share by Product Type, %, 2005-2017
  • Table 48: Synthetic API, Spain, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 49: Synthetic API, Spain, Revenue Share by Customer Base, %, 2005-2017
  • Table 50: Biotech API, Spain, Revenue Analysis by Customer Base, $m, 2005-2017
  • Table 51: Biotech API, Spain, Revenue Share by Customer Base, %, 2005-2017
  • Table 52: API, Spain, Revenue Split by Therapeutic Applications, %, 2011-2017

List of Figures

  • Figure 1: CMO Market, Europe, Difference in Hourly Wage Costs in Euro Area vs. Eastern Europe, 2009
  • Figure 2: API, Europe, Key Benefits of Outsourcing to CMOs, 2011
  • Figure 3: API, CMO Market in the Top Five European Countries Vs Central and Eastern Europe, (%), 2010
  • Figure 4: CMO Market, The Central and Eastern Europe, Revenue Analysis ($bn), 2005-2017
  • Figure 5: Europe API Market, Product Types
  • Figure 6: API, Europe, Value Chain, 2011
  • Figure 7: API, Europe , Total Revenue Analysis , $m, 2005-2017
  • Figure 8: API, Europe, Revenue Share by Product Types, (%), 2011
  • Figure 9: Synthetic API, Europe, Revenue Analysis, ($m), 2005-2017
  • Figure 10: Synthetic API, Europe, Revenue Share Analysis by Countries, (%), 2011
  • Figure 11: Synthetic API, Europe, Comparison of Countries by Revenue Growth Rates, 2011-2017
  • Figure 12: Synthetic API, Europe, Revenue Share Trend Analysis by Countries, (%), 2005-2017
  • Figure 13: Synthetic API, Europe, Revenue Share by Customer Base, (%), 2011
  • Figure 14: Synthetic API, Europe, Revenue Trend by Product Types, ($m), 2011
  • Figure 15: Biotech API, Europe, Revenue Analysis,($m), 2005-2017
  • Figure 16: Biotech API, Europe, Revenue Share by Countries, (%), 2011
  • Figure 17: Biotech API, Europe, Comparison of Revenue Growth Rates by Countries, 2005-2017
  • Figure 18: Biotech API, Europe, Revenue Share Trend, (%), 2005-2017
  • Figure 19: Biotech API, Europe, Revenue Share Analysis by Customer Base, (%), 2011
  • Figure 20: Biotech API, Europe , Revenue Trend Analysis by Product, ($m) Types, 2005-2017
  • Figure 21: API, Europe, Revenue Split by Therapeutic Applications, (%), 2011-2017
  • Figure 22: API, Germany, Revenue Analysis by Product Types, ($m), 2005-2017
  • Figure 23: API, Germany, Revenue Share by Product Type, (%), 2005-2017
  • Figure 24: Synthetic API, Germany, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 25: Synthetic API, Germany, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 26: Biotech API, Germany, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 27: Biotech API, Germany, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 28: API, Germany, Revenue Split by Therapeutic Applications, (%), 2011-2017
  • Figure 29: API, France, Revenue Analysis by Product Types, ($m), 2005-2017
  • Figure 30: API, France, Revenue Share by Product Type, (%), 2005-2017
  • Figure 31: Synthetic API, France, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 32: Synthetic API, France, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 33: Biotech API, France, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 34: Biotech API, France, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 35: API, France, Revenue Split by Therapeutic Applications, (%), 2011-2017
  • Figure 36: API, Italy, Revenue Analysis by Product Types, ($m), 2005-2017
  • Figure 37: API, Italy, Revenue Share by Product Type, (%), 2005-2017
  • Figure 38: Synthetic API, Italy, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 39: Synthetic API, Italy, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 40: Biotech API, Italy, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 41: Biotech API, Italy, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 42: API, Italy, Revenue Split by Therapeutic Applications, (%), 2011-2017
  • Figure 43: API, The UK, Revenue Analysis by Product Types, ($m), 2005-2017
  • Figure 44: API, The UK, Revenue Share by Product Type, (%), 2005-2017
  • Figure 45: Synthetic API, The UK, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 46: Synthetic API, The UK, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 47: Biotech API, The UK, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 48: Biotech API, The UK, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 49: API, The UK, Revenue Split by Therapeutic Applications, (%), 2011-2017
  • Figure 50: API, Spain, Revenue Analysis by Product Types, ($m), 2005-2017
  • Figure 51: API, Spain, Revenue Share by Product Type, (%), 2005-2017
  • Figure 52: Synthetic API, Spain, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 53: Synthetic API, Spain, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 54: Biotech API, Spain, Revenue Analysis by Customer Base, ($m), 2005-2017
  • Figure 55: Biotech API, Spain, Revenue Share by Customer Base, (%), 2005-2017
  • Figure 56: API, Spain, Revenue Split by Therapeutic Applications, (%), 2011-2017
Back to Top